Cargando…
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
Aberrations on TP53, either as deletions of chromosome 17p (del17p) or mutations, are associated with poor outcome in multiple myeloma (MM), but conventional detection methods currently in use underestimate their incidence, hindering an optimal risk assessment and prognostication of MM patients. We...
Autores principales: | Martello, M., Poletti, A., Borsi, E., Solli, V., Dozza, L., Barbato, S., Zamagni, E., Tacchetti, P., Pantani, L., Mancuso, K., Vigliotta, I., Rizzello, I., Rocchi, S., Armuzzi, S., Testoni, N., Marzocchi, G., Martinelli, G., Cavo, M., Terragna, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791929/ https://www.ncbi.nlm.nih.gov/pubmed/35082295 http://dx.doi.org/10.1038/s41408-022-00610-y |
Ejemplares similares
-
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients
por: Martello, Marina, et al.
Publicado: (2022) -
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles
por: Mazzocchetti, G., et al.
Publicado: (2022) -
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
por: Vigliotta, Ilaria, et al.
Publicado: (2022) -
P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
por: Vigliotta, Ilaria, et al.
Publicado: (2023) -
Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)